Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression

被引：0
|
作者：
Kun Wang
Xiaoyong Dai
Albert Yu
Chunyan Feng
Kewei Liu
Laiqiang Huang
机构：
[1] Shenzhen Key Laboratory of Gene and Antibody Therapy,
[2] Center for Biotechnology and Biomedicine,undefined
[3] State Key Laboratory of Chemical Oncogenomics,undefined
[4] State Key Laboratory of Health Sciences and Technology,undefined
[5] Precision Medicine and Healthcare Research Center,undefined
[6] Tsinghua-Berkeley Shenzhen Institute (TBSI),undefined
[7] Institute of Biopharmaceutical and Health Engineering,undefined
[8] Shenzhen International Graduate School,undefined
[9] Tsinghua University,undefined
[10] School of Life Sciences,undefined
[11] Tsinghua University,undefined
来源：
Journal of Experimental & Clinical Cancer Research | / 41卷
关键词：
P-PROTACs; FOXM1; Liver cancer; Breast cancer; GLUT1; PD-L1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression
    Wang, Kun
    Dai, Xiaoyong
    Yu, Albert
    Feng, Chunyan
    Liu, Kewei
    Huang, Laiqiang
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
  • [2] A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells
    Shi, Yu-Ying
    Dong, Di-Rong
    Fan, Gang
    Dai, Meng-Yuan
    Liu, Miao
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [3] Peptide-Based PROTAC Degrader of CDA1 Suppresses Diabetic Kidney Disease
    Wu, Jiao
    Cheng, Shasha
    Zhang, Yingying
    Li, Xiaoyan
    Zhou, Xia
    Li, Xiaogang
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [4] The Interaction of GLUT1 and FOXM1 Leads to a Poor Prognosis in Colorectal Cancer
    Kuai, Xiao-Yi
    Lei, Zhi-Yi
    Liu, Xiao-Shuang
    Shao, Xin-Yu
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2020, 20 (08) : 941 - 950
  • [5] Develop a peptide-based PET radiotracer for imaging PD-L1 expression in cancer
    Hu, Kuan
    Zhang, Ming-Rong
    Hanyu, Masayuki
    Xie, Lin
    Zhang, Yiding
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 : S46 - S47
  • [6] Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer
    Islam, Mohammad Kaisarul
    Stanslas, Johnson
    PHARMACOLOGY & THERAPEUTICS, 2021, 227
  • [7] Peptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer
    Bojko, Magdalena
    Wegrzyn, Katarzyna
    Sikorska, Emilia
    Ciura, Piotr
    Battin, Claire
    Steinberger, Peter
    Magiera-Mularz, Katarzyna
    Dubin, Grzegorz
    Kulesza, Adam
    Sieradzan, Adam K.
    Spodzieja, Marta
    Rodziewicz-Motowidlo, Sylwia
    TRANSLATIONAL ONCOLOGY, 2024, 42
  • [8] FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD-L1 Expression and Cell Proliferation
    Madhi, Hamadi
    Lee, Jeon-Soo
    Choi, Young Eun
    Li, Yan
    Kim, Myoung Hee
    Choi, Yongdoo
    Goh, Sung-Ho
    ADVANCED SCIENCE, 2022, 9 (29)
  • [9] PEPTIDE-BASED RADIOIMMUNOASSAY SPECIFIC FOR GLUT1 GLUCOSE TRANSPORTER
    TSUKUDA, K
    ASANO, T
    LIN, JL
    KATAGIRI, H
    ISHIHARA, H
    TAKAKU, F
    OKA, Y
    DIABETES, 1991, 40 (03) : 315 - 318
  • [10] Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy
    Zhu, Shiyu
    Liang, Beibei
    Zhou, Yuxuan
    Chen, Yinfei
    Fu, Jiayu
    Qiu, Ling
    Lin, Jianguo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (03) : 625 - 640
12345